Clinical trial · no report yet · Phase 2
CAREMM-002
A Study of Bortezomib, Lenalidomide and Dexamethasone (VRd)-Based Regimen Followed by BCMA CAR-T Therapy in Transplant-Ineligible Patients With Primary Plasma Cell Leukemia
- NCT05979363 ↗
- Recruiting
- Institute of Hematology & Blood Diseases Hospital, China
- Focused
We haven't built a report for this trial yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Preliminary discovery
Commentary in our index that names this trial so far
Podcasts, YouTube videos and X posts we have indexed. A report screens them, searches for more and cites what clinicians said when it is built, so final coverage is set at build.
| Channel | Found | |
|---|---|---|
| X threads | 4 |
The trial
ClinicalTrials.gov- Official title
- Safety and Efficiency of VRd Combining BCMA CAR-T Regimen for Transplant-ineligible Patients With Primary Plasma Cell Leukemia: a Prospective, Single-arm, Single-center, Phase II Study.
- Phase
- Phase 2
- Status
- Recruiting
- Conditions
- Plasma Cell Leukemia
- Interventions
- anti-BCMA CAR-T; VRD-based regimen
- Arms
- VRD-based Regimen Combined With BCMA CART · Experimental
- Enrollment
- 20 (estimated)
- Primary outcomes
- Safety and Tolerability
- MRD-negative rate
- Sponsor
- Institute of Hematology & Blood Diseases Hospital, China
- Start
- Aug 14, 2023
- Primary completion
- Jul 1, 2026 (estimated)
- Results posted
- No
- Registry record
- NCT05979363 · updated Aug 3, 2025